Health Care Equipment & Services

Progyny Inc. tops Q1 2026 earnings, raising full‑year revenue and EBITDA forecasts amid expanding fertility‑benefits demand and cost‑control gains.

Explore LENSAR, Inc.’s cutting‑edge laser tech for cataract surgery and its volatile financial journey—innovation meets risk in healthcare investing.

Concentra Group Holdings Parent Inc. faces market volatility and strategic doubts, urging investors to scrutinize its healthcare growth plans and transparency.

Teleflex Q1 2026 earnings beat analysts, projects 4.5‑5.5 % revenue growth, launches a $1 bn share‑buyback and streamlines its portfolio with divestitures.

Scienture Holdings secures $11 M non‑dilutive debt and a third liquid losartan patent, fueling product roll‑out, R&D, and shareholder value in healthcare tech.

Privia Health Group’s Q1 2026 results show tech‑driven growth, yet margin pressure and costly AI upgrades test its high valuation—can strategic board moves turn the tide?

Castle Biosciences’ high‑profile hype vs. its real challenges: one test, limited earnings, and a questionable skin‑cancer PR push. Understand the risks before buying.

Philips reports a 6% rise in Q1 2026 order intake and 4% sales growth, with EBITA margins up 40bp and strong cash flow, reaffirming a robust 2026 outlook.

Explore DorsaVi Ltd’s cutting‑edge wireless sensor tech that tracks workplace and sports injuries—discover how its real‑time data boosts prevention and recovery.

Ardent Health Inc. gears up for Q1 2026 earnings, spotlighting its growth plans, cost controls, and patient‑care expansion—key insights for investors.